Insurers pay docs to stick to regimens

Share this article:

Insurance companies are getting more closely involved with cancer treatment options. The Wall Street Journal reports that the strategies include WellPoint's latest rollout—a $350 per-month, per-patient incentive for doctors who adhere to the insurer's recommended regimens—as well as insurer Highmark, which eliminated the pay reimbursement differential between hospital and in-office settings. Highmark's chief medical officer said they found they were being charged hospital rates even when a medication was given at an office, saying “they simply relabeled the room” to get the higher reimbursement rate.

WellPoint estimates that the program will end up saving the insurer around $5.4 billion. The company told the WSJ that its policy will not clash with genetics-based protocols and that it will not punish doctors for using treatments that are not on its recommended list.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.